Conferences: SIRS

SIRS

SIRS 2024

Long-Term Metabolic Outcomes Associated With KarXT (Xanomeline and Trospium): Interim Results From Pooled, Long-Term Safety Studies EMERGENT-4 and EMERGENT-5

SIRS 2024

The Impact of KarXT on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Phase 3 Trials

SIRS 2024

Maintenance of Efficacy of KarXT (Xanomeline and Trospium) in Schizophrenia

SIRS 2024

Long-Term Safety of KarXT (Xanomeline and Trospium) in Schizophrenia

SIRS 2024

Blinded Remote Ratings of Site-Based PANSS Interviews Address Functional Unblinding in a Study of Acute Exacerbation of Psychosis in Schizophrenia

SIRS 2023 

Safety and Efficacy of KarXT in Patients With Schizophrenia in the Randomized, Double-Blind, Placebo-Controlled, Phase 3 EMERGENT-2 and EMERGENT-3 Trials 

SIRS 2023 

The Role of M1 and M4 Muscarinic Receptors in Cognitive Performance 

SIRS 2022

The Muscarinic Agonist Xanomeline Demonstrates Standalone Activity and Augments Clinical Antipsychotics in Rodent Behavioral Models of Psychosis

SIRS 2022

Acetylcholine as a Regulator of Dopamine Pathways: Rationale for Selective Muscarinic Agonists as Candidates for Antipsychotic Drug Development

SIRS 2022

The Potential of M1 Agonists to Treat Cognitive Impairment: Evidence From a Phase 2 Study of KarXT in Schizophrenia (EMERGENT-1)